TuisMOLN • NASDAQ
add
Molecular Partners AG
Vorige sluiting
$4,32
Dagwisseling
$4,32 - $4,70
Jaarwisseling
$3,32 - $12,70
Markkapitalisasie
178,36 m USD
Gemiddelde volume
2,52 k
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 0,00 | -100,00% |
Bedryfskoste | 52,85 m | 815,93% |
Netto inkomste | -11,23 m | 43,22% |
Netto winsgrens | — | — |
Wins per aandeel | -0,30 | — |
EBITDA | -14,22 m | 13,35% |
Effektiewe belastingkoers | -0,02% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 149,44 m | -20,04% |
Totale bates | 158,53 m | -20,08% |
Totale aanspreeklikheid | 16,89 m | -22,95% |
Totale ekwiteit | 141,64 m | — |
Uitstaande aandele | 36,71 m | — |
Prys om te bespreek | 1,12 | — |
Opbrengs op bates | -23,65% | — |
Opbrengs op kapitaal | -25,90% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -11,23 m | 43,22% |
Kontant van bedrywe | -13,20 m | 17,47% |
Kontant van beleggings | -4,49 m | -123,10% |
Kontant van finansiering | 15,30 m | 5 234,56% |
Netto kontantverandering | -1,88 m | -72,29% |
Beskikbare kontantvloei | -12,16 m | -29,92% |
Meer oor
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Gestig
2004
Webwerf
Werknemers
162
